GSK has announced that its new gene therapy for a rare genetic disorder has shown a 95% success rate in clinical trials, marking a significant breakthrough in the treatment of genetic diseases.
The Science Behind the Gene Therapy
The new gene therapy uses a novel approach to edit the genes responsible for the disorder, providing a permanent cure for the disease. The gene therapy has been shown to be safe and well-tolerated in clinical trials.
The gene therapy has demonstrated a significant improvement in patient outcomes, with a 90% reduction in disease-related symptoms.
The results of our clinical trials are promising, and we believe that our new gene therapy has the potential to make a significant impact on the lives of patients with this rare genetic disorder, said Emma Walmsley, CEO of GSK.